BridgeBio Pharma Inc
NASDAQ:BBIO

Watchlist Manager
BridgeBio Pharma Inc Logo
BridgeBio Pharma Inc
NASDAQ:BBIO
Watchlist
Price: 26.44 USD -2.76% Market Closed
Market Cap: 5B USD
Have any thoughts about
BridgeBio Pharma Inc?
Write Note

BridgeBio Pharma Inc
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

BridgeBio Pharma Inc
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
BridgeBio Pharma Inc
NASDAQ:BBIO
Revenue
$217.8m
CAGR 3-Years
56%
CAGR 5-Years
52%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Revenue
$55.5B
CAGR 3-Years
0%
CAGR 5-Years
11%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Revenue
$28.3B
CAGR 3-Years
1%
CAGR 5-Years
5%
CAGR 10-Years
3%
Amgen Inc
NASDAQ:AMGN
Revenue
$32.5B
CAGR 3-Years
8%
CAGR 5-Years
7%
CAGR 10-Years
5%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Revenue
$10.6B
CAGR 3-Years
14%
CAGR 5-Years
24%
CAGR 10-Years
30%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Revenue
$13.8B
CAGR 3-Years
1%
CAGR 5-Years
16%
CAGR 10-Years
18%
No Stocks Found

BridgeBio Pharma Inc
Glance View

Market Cap
5B USD
Industry
Biotechnology

BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. The company is headquartered in Palo Alto, California and currently employs 576 full-time employees. The company went IPO on 2019-06-27. The Company’s product platform divided into three key categories: Mendelian, Oncology and Gene therapy. The Company’s pipeline programs include product candidates ranging from early discovery to late-stage development. The Company’s products include BBP-561, BBP-711, BBP-631 and BBP-454.

BBIO Intrinsic Value
29.51 USD
Undervaluation 10%
Intrinsic Value
Price

See Also

What is BridgeBio Pharma Inc's Revenue?
Revenue
217.8m USD

Based on the financial report for Sep 30, 2024, BridgeBio Pharma Inc's Revenue amounts to 217.8m USD.

What is BridgeBio Pharma Inc's Revenue growth rate?
Revenue CAGR 5Y
52%

Over the last year, the Revenue growth was 2 209%. The average annual Revenue growth rates for BridgeBio Pharma Inc have been 56% over the past three years , 52% over the past five years .

Back to Top